Brought to you by 
Pfizer, Karo Bio AB team up in the area of autoimmune disorders
05 Sep 2013
Executive Summary
Pfizer Inc. has partnered with Karo Bio AB (nuclear receptor therapeutic protein targets) for the discovery and development of small-molecule retinoic acid-related orphan receptor (ROR-gamma) modulators for autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer, Karo Bio AB team up in the area of autoimmune disorders
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice